Advertisement

Endocrine

, Volume 13, Issue 2, pp 193–199 | Cite as

Use of sibutramine and other noradrenergic and serotonergic drugs in the management of obesity

  • Donna H. Ryan
Article

Abstract

Drugs that act through noradrenergic and serotonergic mechanisms have historically served as the mainstays of pharmacologic treatments for obesity. This review addresses the following three topics: a brief discussion of older weight loss medications approved for short-term use (benzphetamine, phendimetrazine, diethylpropion, mazindol, and phentermine), as well as over-the-counter adrenergic drugs (phenylpro-panolamine and ephedrine); recent clinical studies documenting the safety and efficacy of a new medication for obesity treatment, sibutramine, recently approved by the Food and Drug Administration for long-term use; and recent studies characterizing the valvulopathy associated with fenfluramine and dexfenfluramine, serotonergic medications for obesity which have been removed from the markets.

Key Words

Anorexiant valvulopathy pharmacotherapy noredrenergic serotonergic sibutremine 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    National Institutes of Health and National Heart, Lung and Blood Institute (1998). Obes. Res. 6, 51S-210S.Google Scholar
  2. 2.
    Bray, G. A. (1991). Ann. Intern. Med. 115, 152–153.PubMedGoogle Scholar
  3. 3.
    Bray, G. A. (1999). Ann. Intern. Med. 31, 1–3.Google Scholar
  4. 4.
    Weintraub, M., Sundaresan, P. R., Madan, M., Schuster, B., Balder, A., Lasagna, L., and Cox, C. (1992). Clin. Pharmacol. Ther. 51, 586–594.PubMedCrossRefGoogle Scholar
  5. 5.
    Weintraub, M., Sundaresan, P. R., Schuster, B., Ginsberg, G., Madan, M., Balder, A., Stein, E. C., and Byrne, L. (1992). Clin. Pharmacol. Ther. 51, 595–601.PubMedCrossRefGoogle Scholar
  6. 6.
    Weintraub, M., Sundaresan, P. R., Schuster, B., Moscucci, M., and Stein, E. C. (1992). Clin. Pharmacol. Ther. 51, 602–607.PubMedCrossRefGoogle Scholar
  7. 7.
    Weintraub, M., Sundaresan, P. R., Schuster, B., Averbuch, M., Stein, E. C., Cox, C., and Byrne, L. (1992). Clin. Pharmacol. Ther. 51, 608–614.PubMedCrossRefGoogle Scholar
  8. 8.
    Weintraub, M., Sundaresan, P. R., Schuster, B., Averbuch, M., Stein, E. C., and Byrne, L. (1992). Clin. Pharmacol. Ther. 51, 615–618.PubMedCrossRefGoogle Scholar
  9. 9.
    Connolly, H. M., Crary, J. L., McGoon, M. D., Hensrud, D. D., Edwards, B. S., Edwards, W. D., and Schaff, H. V. (1997). N. Engl. J. Med. 337, 581–588.PubMedCrossRefGoogle Scholar
  10. 10.
    American Home Products Unveils Fen-Phen Settlement Plan. Reuters Health. (1999).Google Scholar
  11. 11.
    Bray, G. A. and Greenway, F. L. (1999). Endocr. Rev. 20, 805–875.PubMedCrossRefGoogle Scholar
  12. 12.
    Munro, J. F., MacCuish, A. C., Wilson, E. M., and Duncan, L. F. P. (1968). BMJ 1, 352–356.PubMedCrossRefGoogle Scholar
  13. 13.
    Weintraub, M. (1985). Clin. Pharmacol. Ther. 5, 53–79.Google Scholar
  14. 14.
    Morgan, J. P. and Funderburk, F. R. (1992). Am. J. Clin. Nutr. 55, 206S-210S.PubMedGoogle Scholar
  15. 15.
    Astrup, A., Breum, L., Toubro, S., Hein, P., and Quaade, F. (1992). Int. J. Obes. Relat. Metab. Disord. 16, 169–277.Google Scholar
  16. 16.
    Connoley, J. P., Liu, Y. L., Frost, I., Reckless, I. P., Heal, D. J., and Stock, M. J. (1999). Br. J. Pharmacol. 126, 1487–1495.PubMedCrossRefGoogle Scholar
  17. 17.
    Stock, M. J. (1997). Int. J. Obes. 21, S25-S29.Google Scholar
  18. 18.
    Rolls, B. J., Shide, D. J., Thorwart, M. L., and Ulbrecht, J. S. (1998). Obes. Res. 6, 1–11.PubMedGoogle Scholar
  19. 19.
    Chapelot, D., Marmonier, C., Thomas, F., and Hanotin, C. (2000). Physiol. Behav. 58, 299–308.CrossRefGoogle Scholar
  20. 20.
    Halford, J. L. G., Heal, D. J., and Blundell, J. E. (1994). Appetite 23, 306–307.Google Scholar
  21. 21.
    Seagle, H. M., Bessessen, D. H., and Hill, J. O. (1998). Obes. Res. 6, 115–121.PubMedGoogle Scholar
  22. 22.
    Hansen, D. L., Toubro, S., Stock, M. J., Macdonald, I. A., and Astrup, A. (1998). Am. J. Clin. Nutr. 6, 1180–1186.Google Scholar
  23. 23.
    Hansen, D. L., Toubro, S., Stock, M. J., Macdonald, I. A., and Astrup, A. (1999). Int. J. Obes. Relat. Metab. Disord. 23, 1016–1024.PubMedCrossRefGoogle Scholar
  24. 24.
    Walsh, K. M., Lean, E., and Lean, M. E. (1999). Int. J. Obes. Relat. Metab. Disord. 23, 1009–1015.PubMedCrossRefGoogle Scholar
  25. 25.
    Weintraub, M., Rubio, A., Golik, A., Byrne, L., and Scheinbaum, M. L. (1991). Clin. Pharmacol. Ther. 50, 330–337.PubMedCrossRefGoogle Scholar
  26. 26.
    Ryan, D. H., Kaiser, P., and Bray, G. A. (1995). Obes. Res. 3, 553–559.Google Scholar
  27. 27.
    Bray, G. A., Ryan, D. H., Gordon, D., Heidingsfelder, S., Cerise, F., and Wilson, K. (1996). Obes. Res. 4, 263–270.PubMedGoogle Scholar
  28. 28.
    Lean, M. E. (1997). Int. J. Obes. 21, S30-S36.Google Scholar
  29. 29.
    Hanotin, C., Thomas, F., Jones, S. P., Leutenegger, E., and Drouin, P. (1998). Int. J. Obes. Relat. Metab. Disord. 22, 32–38.PubMedCrossRefGoogle Scholar
  30. 30.
    Bray, G. A., Blackburn, G. L., Ferguson, J. M., Greenway, F. L., Jain, A. K., Mendel, C. M., Mendels, J., Ryan, D. H., Schwartz, S. L., Scheinbaum, M. L., and Seaton, T. B. (1999). Obes. Res. 7, 189–198.PubMedGoogle Scholar
  31. 31.
    Apfelbaum, M., Vague, P., Ziegler, O., Hanotin, C., Thomas, F., and Leutenegger, E. (1999). Am. J. Med. 106, 179–184.PubMedCrossRefGoogle Scholar
  32. 32.
    Cuellar, G. E., Ruiz, A. M., Monsalve, M. C., and Berber, A. (2000). Obes. Res. 8, 71–82.PubMedCrossRefGoogle Scholar
  33. 33.
    Fanghanel, G., Cortinas, L., Sanchez-Reyes, L., and Berber, A. (2000). Int. J. Obes. Relat. Metab. Disord. 24, 144–150.PubMedCrossRefGoogle Scholar
  34. 34.
    Bach, D. S., Rissanen, A. M., Mendel, C. M., Shepherd, G., Weinstein, S. P., Kelly, F., Seaton, T. B., Patel, B., Pekkarinen, T. A., and Armstrong, W. F. (1999). Obes. Res. 7, 363–369.PubMedGoogle Scholar
  35. 35.
    Schuh, L. M., Schustser, C. R., Hopper, J. A., and Mendel, C. M. (2000). Psychopharmacology 147, 339–346.PubMedCrossRefGoogle Scholar
  36. 36.
    James, P., Astrup, A., Finer, N., Hilsted, J. Kopelman, P., Rossner, S., Saris, W., and Van Gaal, L. (1999). Obes. Res. 7(Suppl. 1), 50S.Google Scholar
  37. 37.
    Fujioka, K., Seaton, T. B., Rowe, E., Jelinek, C. A., Raskin, P., Lebovitz, H. E., Weinstein, S. P., and the Sibutramine/Diabetes Clinical Study Group. (2000). Diabetes, Obesity and Metabolism 2, 1–13.CrossRefGoogle Scholar
  38. 38.
    McMahon, F. G., Fujioka, K., Singh, B. N., Mendel, C. M., Rowe, E., Rolston, K., Johnson, F., and Mooradian, A. D. (2000). Arch. Intern. Med. 160, 2185–2191.PubMedCrossRefGoogle Scholar
  39. 39.
    Rissanen, T., Pekkarinen, T., Heinanen, T., Saltevo, J., and Taskinen, M. R. (1999). Obes. Res. 7(Suppl. 1), 93S.Google Scholar
  40. 40.
    Griffiths, J., Byrnes, A. E., and Frost, G. (1995). Int. J. Obes. 19(Suppl. 2), 41.Google Scholar
  41. 41.
    Khan, M. A., Herzog, C. A., St. Peter, J. V., Hartley, G. G., Madlon-Kay, R., Dick, C. D., Asinger, R. W., and Vessey, J. T. (1998). N. Engl. J. Med. 339, 713–718.PubMedCrossRefGoogle Scholar
  42. 42.
    Weissman, N. J., Tighe, J. F., Gottdiener, J. S. and Gwynne, J. T. (1998). for the Sustained-Release Dexfenfluramine study Group. N. Engl. J. Med. 339, 725–732.PubMedCrossRefGoogle Scholar
  43. 43.
    Jick, H., Vasilakis, C., Weinrauch, L. A., Meier, C. R., Jick, S. S., and Derby, L. E. (1998). N. Engl. J. Med. 339, 719–724.PubMedCrossRefGoogle Scholar
  44. 44.
    Wadden, T. A., Berkowitz, R. I., Silvestry, F., Vogt, R. A., St. John Sutton, M. G., Stunkard, A. J., Foster, G. D., and Aber, J. L. (1998). Obes. Res. 6, 278–284.PubMedGoogle Scholar
  45. 45.
    Wee, C. C., Phillips, R. S., Aurigemma, G., Erban, S., Kriegel, G., Riley, M., and Douglas, P. S. (1998). Ann. Intern. Med. 129, 870–874.PubMedGoogle Scholar
  46. 46.
    Ryan, D. H., Bray, G. A., Helmcke, F., Sander, G., Volaufova, J., Greenway, F., Subramaniam, P., and Glancy, D. L. (1999). Obes. Res. 7, 313–322.PubMedGoogle Scholar
  47. 47.
    Connolly, H. M. and McGoon, M. D. (1999). Curr. Prob. Cardiol. 24, 751–792.CrossRefGoogle Scholar
  48. 48.
    Cannistra, L. B. and Cannistra, A. J. (1998). N. Engl. J. Med. 339, 771.PubMedCrossRefGoogle Scholar
  49. 49.
    Hensrud, D. D., Conolly, H. M., Grogan, M., Miller, P. A., and Jensen, M. D. (1999). Mayo Clin. Proc. 74, 1302–1304.Google Scholar
  50. 50.
    Ryan, D. H., Bray, G. A., Greenway, F. L., and Helmcke, F. (1999). Obes. Res. 7(Suppl. 1), 50S.Google Scholar
  51. 51.
    Weyer, C., Gautier, J. F., and Danforth, E. (1999). Diabetes Metab. 25, 11–21.PubMedGoogle Scholar
  52. 52.
    World Health Organization. (1998). Obesity-Preventing and Managing the Global Epidemic. Report of a WHO Consultancy on Obesity, Geneva, 3–5 June, 1997. WHO: Geneva.Google Scholar
  53. 53.
    Bray, G. A. (1998). Lancet 352, 160–161.PubMedCrossRefGoogle Scholar
  54. 54.
    Colditz, G. A., and Coakley, E. (1997). Int. J. Sports Med. 18, S162-S170.PubMedCrossRefGoogle Scholar

Copyright information

© Human Press Inc 2000

Authors and Affiliations

  1. 1.Pennington Biomedical Research CenterBaton Rouge

Personalised recommendations